Facts & Resources
Learn more about cervical cancer and find helpful resources
Related Articles
Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma
Latest News The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16,
Aspiring Professional Musician Finds Success in Moffitt’s Arts in Medicine Program
Corbin Smith is one of five artists-in-residence at the cancer center
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients…
Welcome! You are invited to join a webinar: AHNS Virtual Education Series: From the Bench to the Bedside: Using Preclinical Models to Advance the Management of Head and Neck Cancer. After registering, you will receive a confirmation email about joining the webinar.
January 22, 2025 Learning Objectives: Define the spectrum of contemporary preclinical models of HNSCC. Describe the strengths and weaknesses of contemporary preclinical models of HNSCC.…
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer | Cancer Today
Recent findings support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months.
Fox Chase Cancer Center Welcomes Dr. Qing Chen
Qing Chen, MD, PhD, has joined as a new assistant professor in the Cancer Signaling and Microenvironment Research Program.